MMP9 and glioblastoma: Moreover, a randomized phase III study has shown that newly diagnosed GBM patients with low MMP9 plasma levels respond better to bevacizumab, with an improved OS, reinforcing the hypothesis of its concrete involvement in GBM angiogenesis [218].